So, on the strength of that trial, Blackman and Grant paid $1 million (plus $10 million in Day One stock) to Takeda and $2 ...

Chakravarthi AVPS, Chairman of the Federation of Pharma Entrepreneurs, provides an overview of global strategies to accelerate access to innovative therapies, bridging equity, regulation, and ...

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Mackinnon, senior vice president ...

Pfizer has claimed its first regulatory approval for a GLP-1 agonist in obesity, getting a green light in China for ecnoglutide, a once-weekly injectable drug licensed from Hangzhou-based Sciwind ...

Rumours earlier this week of an imminent takeover offer for Day One Biopharmaceuticals proved well-founded, but missed the mark on the identity of the acquirer. France's Servier has emerged as the ...

Roche licensed petrelintide from Zealand last year for a hefty $1.4 billion upfront payment, adding it to a portfolio of half a dozen clinical-stage candidates, including dual GIP/GLP-1 agonist CT-388 ...

Alnylam is broadening its position in the area of RNA interference (RNAi) gene-silencing therapies for cardiovascular diseases via a partnership with Tenaya Therapeutics, claiming rights to use the ...

Daiichi Sankyo's European division has signed a partnership with German digital health company GAIA to sell a digital therapeutic (DTx) designed to support people with high cholesterol levels. The DTx ...

With the increase in wellness brands competing for audience attention, it’s more important than ever that pharma marketers tell their stories clearly and creatively, with a focus on educating ...

Johnson & Johnson's Tecvayli has been approved as part of a combination regimen with its Genmab-partnered Darzalex Faspro as a second-line therapy for relapsed or refractory multiple myeloma, just 55 ...

Cardiff, Wales-based Antiverse's computational platform has been set up to find antibodies against challenging drug targets, ...

The FDA has started a review of Hansa Biopharma's imlifidase for patients who need a kidney transplant, but for whom finding ...